Clinical Trial Keywords
Hepatocellular Carcinoma (HCC); Biliary tract cancer (BTC); Cholangiocarcinoma; Liver Cancer; Immunotherapy; Fibrolamellar hepatocellular carcinoma (FLC)
Clinical Trials
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer Pancreatic Cancer
DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma Fibrolamellar Hepatocellular Carcinoma (FLC)
A multicenter Phase 2 of atezolizumab with or without cobimetinib in patients with advanced biliary tract cancer, conducted through the NCI Experimental Therapeutics Clinical Trials Network (ETCTN) Study. Role: Co-PI
A single center neoadjuvant study of cabozantinib plus nivolumab in patients with potentially resectable hepatocellular carcinoma (HCC). Role: PI
A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. Role: Co-PI
A study of perioperative nivolumab with or without relatlimab in patients with resectable hepatocellular carcinoma (HCC). Role: PI
Selected Publications
View all on PubMed
Yarchoan M, Cope L, Anders RA, Noonan A, Goff LW, Goyal L, Lacy J, Li D, Patel A, He AR, Abou-Alfa G, Spencer K, Kim E, Xavier S, Ruggieri A, Davis SL, McRee A, Kunk P, Zhu Q, Wang-Gillam A, Poklepovic A, Chen H, Sharon E, Lesinski GB, Azad N. A multicenter randomized phase 2 trial of atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers (BTCs): A NCI Experimental Therapeutics Clinical Trials Network (ETCTN) study. AACR Annual Meeting Oral Plenary April 2020
Yarchoan M, Ho WJ, Mohan A, Shah Y, Vithayathil T, Leatherman J, Dennison L, Zaidi N, Ganguly S, Woolman S, Cruz K, Armstrong TD, Jaffee EM. Effects of B cell–activating factor on tumor immunity. JCI Insight. JCI Insight; 2020 May 21;5(10)
Yarchoan M, Huang C, Zhu Q, Ferguson AK, Durham JN, Anders RA, Thompson ED, Rozich NS, Thomas DL, Nauroth JM, Rodriguez C, Osipov A, De Jesus‐Acosta A, Le DT, Murphy AG, Laheru D, Donehower RC, Jaffee EM, Zheng L, Azad NS (2020) A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. Cancer Med 9: 1485–1494, doi:10.1002/cam4.2763
Ho WJ, Zhu Q, Durham J, Popovic A, Xavier S, Leatherman J, Mohan A, Mo G, Zhang S, Gross N, Charmsaz S, Lin D, Quong D, Wilt B, Kamel IR, Weiss M, Philosophe B, Burkhart R, Burns WR, Shubert C, Ejaz A, He J, Deshpande A, Danilova L, Stein-O’Brien G, Sugar EA, Laheru DA, Anders RA, Fertig EJ, Jaffee EM, Yarchoan M. Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity. Nat Cancer. 2021 Jul 29;1–13
Yarchoan M, Hopkins A, Jaffee EM (2017) Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med 377: 2500–2501. PMCID: PMC6549688
